4.6 Article

Analytical Performance of a Novel Latex Turbidimetric Immunoassay, Nanopia TARC, for TARC/CCL17 Measurement: A Retrospective Observational Study

期刊

DIAGNOSTICS
卷 13, 期 18, 页码 -

出版社

MDPI
DOI: 10.3390/diagnostics13182935

关键词

TARC; CCL17; latex turbidimetric immunoassay; atopic dermatitis; biomarker

向作者/读者索取更多资源

The analytical performance of a novel latex turbidimetric immunoassay method, Nanopia TARC, was evaluated on residual serum samples from patients with skin or allergic diseases.
Thymus- and activation-regulated chemokine (TARC, also known as CCL17) is used as a biomarker for atopic dermatitis. The methods currently used for its measurement are complex, time-consuming, and require large machinery, warranting the need for a method that is simple, has a quick turnaround time, and requires less complex machinery. We evaluated the analytical performance of a novel latex turbidimetric immunoassay method, Nanopia TARC, on 174 residual serum samples from patients with skin or allergic diseases. This evaluation included the assessment of the limit of blank/detection/quantification (LOB/D/Q), precision, accuracy, linearity, interference, and commutability between Nanopia TARC and HISCL TARC, based on the chemiluminescent enzyme immunoassay (CLEIA) method. The LOB/D/Q values were 13, 57, and 141 pg/mL, respectively. The coefficient of variation of the repeatability was 0.9-3.8%, and that of the intermediate precision was 2.1-5.4%. The total error of the accuracy was 1.9-13.4%. The linearity was 141 and 19,804 pg/mL for TARC. The correlation coefficient between Nanopia TARC and HISCL TARC determined using the Passing-Bablok regression analysis was 0.999. Furthermore, the concordance of diagnostic criteria with AD was 92%. Nanopia TARC was confirmed to have the same analytical performance for TARC measurement as the existing CLEIA method.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据